Improvement of different menopausal symptoms under the use of the nutritional menopausal product Exelvit Menopausia - Menoxel -1

Chemo Group0 个研究点目标入组 160 人开始时间: 2022年6月22日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Female patients, age = 50 years and being menopausal according to clinical symptoms
•2. FSH (> 50 mIU/mL) and Estradiol (< 30 pg/mL)
•3. Written informed Consent

•1. Current BMI > 35 kg/m2
•2. Patients with severe acute or chronic diseases (e.g. pancreatitis, hypertriglyceridemia, liver disease, malign or benign tumor of the liver, malign sex-hormone-dependent diseases of the genital or the breast)
•3. Migraine with Aura
•4. Intake of drugs, which induce microsomal enzymes, especially cytochrome-P450, e.g. phenytoine, phenobarbital, pyrimidon, bosentan, carbamazepin, rifampicin, topiramate, felbamate, griseofulvine, some HIV protease inhibitors (e.g. ritonavir) und non-nucleosidic inhibitors of reverse transciptase (e.g. efavirenz) and androgen receptor (AR) antagonists (e.g. enzalutamide).
•5. History of cardiocascular disease
•6. Advanced high blood pressure or diabetes mellitus
•7. Existence or known risk for venous or arterial thromboembolism
•8. Non-diagnosed abnormous vaginal bleeding
•9. Use of drugs containing Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir during the study period and two weeks in advance
•10. Pregnancy and Breast feeding during the study period
•11. Allergy to one of the compounds of the product
•12. Concomitant use of other nutritional products or female sexual hormones during the study and 8 weeks before

发起方

Chemo Group